Exact Sciences — Aug 6, 2025 release

GAAP to Non-GAAP Measures (Unaudited) (Amounts in thousands) Three Months Ended June 30, 2025 Gross Profit Research & Development Expenses Sales & Marketing Expenses General & Administrative Expenses Income (Loss) from Operations Net Income (Loss) Before Tax Income Tax Benefit (Expense) Net Income (Loss) Net Income (Loss) Per Share Reported $ 562,453 $ 108,901 $ 247,118 $ 208,582 $ (2,148) $ (57) $ (1,128) $ (1,185) $ (0.01) Reported percent of revenue 69  % 13  % 30  % 26  % Amortization of acquired intangible assets 21,967 (270) (1,924) (26) 24,187  24,187  240  24,427  0.12  Acquisition and integration costs (2) — — — (4,910) 4,910  4,910  (32) 4,878  0.02  Restructuring and business transformation (5) 47 (324) (4,229) (10,640) 15,240  15,240  (63) 15,177  0.08  Rounding adjustment from basic to diluted shares (7) — — — — —  —  —  —  0.01  Adjusted (non-GAAP) $ 584,467 $ 108,307 $ 240,965 $ 193,006 $ 42,189  $ 44,280  $ (983) $ 43,297  $ 0.22  Adjusted percent of revenue (non-GAAP) 72  % 13  % 30  % 24  % Weighted average common shares outstanding - basic 188,902  Weighted average common shares outstanding - diluted 199,831  Six Months Ended June 30, 2025 Gross Profit Research & Development Expenses Sales & Marketing Expenses General & Administrative Expenses Income (Loss) from Operations Net Income (Loss) Before Tax Income Tax Benefit (Expense) Net Income (Loss) Net Income (Loss) Per Share Reported $ 1,063,000 $ 214,211 $ 511,428 $ 429,268 $ (98,158) $ (101,048) $ (1,352) $ (102,400) $ (0.55) Reported percent of revenue 70  % 14  % 34  % 28  % Amortization of acquired intangible assets 42,735 (1,653) (3,847) (52) 48,287  48,287  (830) 47,457  0.25  Acquisition and integration costs (2) — — — (13,196) 13,196  13,196  (52) 13,144  0.07  Impairment of long-lived and indefinite-lived assets (3) — — — — 6,251  6,251  —  6,251  0.03  Restructuring and business transformation (5) 389 (751) (10,160) (28,728) 40,028  40,028  (123) 39,905  0.21  Rounding adjustment from basic to diluted shares (7) — — — — —  —  —  —  0.01  Adjusted (non-GAAP) $ 1,106,124 $ 211,807 $ 497,421 $ 387,292 $ 9,604  $ 6,714  $ (2,357) $ 4,357  $ 0.02  Adjusted percent of revenue (non-GAAP) 73  % 14  % 33  % 26  % Weighted average common shares outstanding - basic 187,863  Weighted average common shares outstanding - diluted 189,416  EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation U.S. GAAP to Non-GAAP Measures (Unaudited) (Amounts in thousands) Three Months Ended June 30, 2024 Gross Profit Research & Development Expenses Sales & Marketing Expenses General & Administrative Expenses Income (Loss) from Operations Net Income (Loss) Before Tax Income Tax Benefit (Expense) Net Income (Loss) Net Income (Loss) Per Share Reported $